Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Standardized mortality ratio (SMR) with second breast events (contralateral in situ or ipsilateral or contralateral invasive breast cancer) after diagnosis of first in situ breast cancer and its 95 % CI, by type of second breast event and family history

From: The impact of in situ breast cancer and family history on risk of subsequent breast cancer events and mortality - a population-based study from Sweden

  All No family history Family history <50 >50
Deaths (n) SMR Deaths (n) SMR Deaths (n) SMR Deaths (n) SMR Deaths (n) SMR
(95 % CI) (95 % CI) (95 % CI) (95 % CI) (95 % CI)
Overall 1343 1.28 1258 1.2 85 1.44 122 2.19 1221 1.24
(1.2–1.2) (1.2–1.4) (1.2–1.8) (1.8–2.6) (1.2–1.3)
No event + 2nd contralateral in situ 927 1.01 875 1.0 52 1.02 58 1.17 869 1.00
(1.0–1.1) (0.9–1.1) (0.8–1.3) (0.8–1.5) (0.9–1.1)
Second invasivea 132 2.06 122 2.03 10 2.54 29 8.03 103 1.7
(1.7–2.4) (1.7–2.4) (1.2–4.7) (5.4–11.5) (1.4–2.1)
Second ipsilateral invasive 63 2.16 58 2.12 5b 2.75 17 12.89 46 1.65
(1.7–2.8) (1.6–2.7) (0.9–6.4) (7.5–20.6) (1.2–2.2)
Second contralateral invasive 55 1.99 49 1.92 6b 2.82 10 7.85 45 1.71
(1.5–2.6) (1.4–2.5) (1.0–6.2) (3.8–14.4) (1.2–2.3)
  1. aIncludes ipsilateral, contralateral and missing side. bOne subject had both ipsilateral and contralateral invasive breast cancer, which is why the total is 6 + 5 = 11 > 10